INTRODUCTION
In mammalian cells, there is evidence for the existence of at least two types of neuraminidases. One of them is responsible for the hydrolysis of gangliosides, the other one attacks glycoproteins and sialyloligosaccharides (3, 12) .
A glycoprotein neuraminidase deficiency has been described in several clinically distinct genetic disorders. In the sialidoses, glycoprotein neuraminidase deficiency is the primary defect (for review see 12) . A further group of patients has been desc~ibed with coexistent deficiencies of neuraminidase and B-galactosidase (8, 17) . It is proposed that this combined 8-galactosidase/neuraminidase deficiency is caused by a defective 32 000-dalton glycoprotein which is normally required to protect these enzymes against excessive intralysosomal degradation and to give these enzvmes their full hvdrolvtic activity (1) . In I-cell disease (muEolipidosis 11) aid in-pseudo-~urler polydystrophy (mucolipidosis 111) neuraminidase deficiency is one of several acid hvdrolase deficiencies caused by insufficient intracellular retention of these enzymes due to deficient UDP-N-acetylglucosamine: lysosomal enzyme N-acetylglucosamine-1-phosphotransferase activity (7, 20) . This is the first report describing a partial neuraminidase deficiency coexistent with a deficiency of N-acetylgalactosamine-6-sulfate (GalNAc-6-S) sulfatase. An isolated defect of this sulfatase is characteristic of Morquio disease type A (mucopolysaccharidosis IV A) (13, 22) . Morquio disease is a rare inherited disorder of glycosaminoglycan catabolism characterized clinically by dysproportionate dwarfism, spondyloepiphysial dyspJasia, dental anomalies, corneal clouding, but normal intelligence (for reviews see 10, 14) . In most cases the patients excrete elevated amounts of keratan sulfate in their urine (18) and store this polysaccharide in cartilage (19) and liver (1 6) .
CLINICAL DESCRIPTION
M.Q., a boy of Austrian origin, was born in 1977 from healthy, unrelated parents by a Cesarian sectio. The birth weight was 3410 g, the body length 54 cm. The first clinical symptom, pectus carinatum, was observed by the parents soon after birth. At the ase of 1 8/12 v he was diasnosed as sufferins from Hunter disease. However, on the occasion oi a prenatal diagnosis during a further pregnancy of his mother, the enzymatic analysis of his fibroblasts revealed normal activitv of iduronide 2-sulfate sulfatase. the enzyme deficient in Hunter's disease, but deficiencies of glycoprotein neuraminidase and GalNAc-6-S sulfatase. Clinical examination at the age of 4 2/12 y revealed an alert child with normal behaviour and normal intelligence. The stature was short (body length 88.5 cm, below the 3rd percentile), the weight was 13.5 kg (below the 3rd percentile). Head circumference and configuration were normal in accordance with age, but appeared too large with respect to body length. The neck and trunk were short, the sternum protruded, and there was a scoliosPs of the spine and a thoracolumbar kyphosis. The hands appeared clumsy. Motility was moderately limited in the hip and the finger phalanges.
The roentgenologic examination at the age of 1 8/12 y revealed signs of dysostosis multiplex with general platyspondyly, tonguelike protrusions of the vertebral bodies, dislocation of the first lumbar vertebra, dysplasia of the acetabular roofs and con'ical appearance of the proximal phalangal ends. The sella turcica appeared normal. Ophthalmologic investigations at the age of 1 8/12 y showed moderate strabismus of the left eye, myopy of both eyes, diffuse clouding of both corneas and essentially normal fundi.
At no occasion typical signs of sialidosis like myoclonus, cherry-red spots of the macula and neurological changes were observed. A younger sister appears healthy.
A normal 46,XY karyotype was found by Giemsa staining, Q-banding, constitutive heterochromatin, R-banding and NOR techniques.
MATERIALS AND METHODS
Fibroblast cultures from patients and from normal individuals were established from skin biopsies and cultured in modified Eagle's minimum essential medium (MEM) as described (2, 25) . From the present patient, skin b8opsies were taken at two occasions. For cell hybridization 5x10 cells of both parental cell lines were mixed one day before fusion and plated in a 25 cm Falcon plastic flask. The fusion procedure was as follows: after rinsing the cells with Hanks' Balanced Salt Solution (BSS), 1.5 ml of 41 % (w/w) polyethylene glycol (PEG) 4000 (Merck, Darmstadt) in MEM with 10 % (w/w) DMSO were added. The solution was rocked for 90 sec, 1.5 ml 41 % PEG in MEM were added, rocked again for 90 sec and then 12 ml Hanks' BSS were added. After 2 min the mixture was removed and the cells were washed twice with Hanks' BSS. After 7 days of cultivation in MEM containing 10 % fetal calf serum the cells were harvested by trypsinization. The cell pellet was washed twice with 0.15 M NaC1, suspended in 0.2 ml water for the determination of GalNAc-6-S sulfatase or in 0.8 ml of 50 mM sodium acetate buffer, pH 4.2, for the determinatlon of neuraminidase, and homogenized by ultrasonication for 3 x 5 sec at 25 W (Labsonic 1510, B. Braun, Melsungen).
Leucocytes from venous blood were collected as quoted earlier (5). Leucocytes from 5 ml blood each were suspended in 0.5 ml 50 mM sodium acetate buffer, pH 4.2 (for neuraminidase assay), and in 0.5 ml water (for the GalIiAc-6-S sulfatase assay), respectively, and homogenized by ultrasonication for 3 x 5 sec.
Glycoprote3n neuryinidase was assayed with a2 * 3 ~ialyl[l-~Hl lactitol (11 NeuAc-H-Lac) and with 4-methylumbelliferyl-Nacetylneuramigic acig (4-MU-NeuAc) (23) as substrates. The preparation of I1 NeuAc-H-Lac has been described (4). The specific radioactivity was 99 Ci/mol. The standard incubation mixture for the neuraminidase assay contained 0.55 nmol substrate, 40-140 ug (fibroblasts) or 280-480 ug (leucocytes)cell protein, 12 umol sodium acetate buffer, pH 4.2, and 0.06 umol sodium azide in a final volume of 140 111 After incubation for 1 h (fibroblasts) or 2 h (leucocytes) at 376 C the reaction was stopped by the addition of 460 111 21 mM NaOH. The incubation mixture was transferred to a 2 ml column of Dowex 1x2, 200-400 mesh, equilibrated with 10 mM Tris/HCl, pH 7.0. The column was wa3hed with 0.5 ml of this buffer, and the reaction product ( [ Hllactitol) was eluted with 4 ml of the same buffer. Kadioactivity was determined after addition of 8 ml Instagel (Packard) .
The determination of GalNAc-6-S sulfatase activity towards 6-sylfo-N-acetylgalactosamine-qlucuronic acid-6-sulfo-N-acetyl-[I-HI galactosaminitol (5) has been described previously (1 1) .
Other lysosomal enzymes (11) and protein (9) were quantitated as described. Sialic acid content in fibroblasts was determined by the method of Warren (241, and in the urine by that of Skoza and Mohos (22) .
Measurement of GalNAc-6-S sulfatase activity in fibroblast homogenates from the patient M.Q. confirmed the diagnosis of Morquio disease tyl5e A. The residual enzyme activity was lower than 1 % of normal activity (table I) with a pH-optimum of 3.0 as expected for the severe form of Morquio disease (6) . The affinity of the mutant enzyme to the trisaccharide substrate was not altered: the k -value of 15 umol/l (data not shown) was the same as that found ?or the normal and the residual GalNAc-6-S sulfatase of Morquio A fibroblasts (6) . The sulfatase activities of the fibroblasts of the patient's parents and sister ranged from 28 to 49 % of normal (table I), as expected for heterozygous individuals.
Glycoprotein neuraminidase activity in fibroblast homogenates from the patient was about 5 % of mean normal activity using either I1 3~e u~c -3~-~a c (table I) (table I) . The k -value of the residual neuraminidase with sialyllactitol as subztrate (0.61 mmol/l) did not differ significantly from the km-value of normal neuraminidase (0.66 mmol/l; data not shown). The same was true for the thermal stability: upon preincubation at 50° C for various lengths of time, the neuraminidase of'mutant and normal cells lost half of its activity after 8 and 10 minutes, respectively. Upon mixing of cell homogenates from the patient and a normal individual, neuraminidase activity corresponding to the calculated average was found (table 111) . This argues against the presence of a reversibly acting inhibitor or the absence of an activator for the neuraminidase in the patient's cells.
In contrast to the findinss in fibroblasts. neuraminidase activity of the patient's pe;ipheral leucocytes was within the normal range, whereas the activity of GalNAc-6-S sulfatase was reduced to 3 % of mean normal activity (table IV) .
To elucidate the genetic background of this coexistent deficiencies of GalNAc-6-S sulfatase and neuraminidase in the fibroblasts of the patient, complementation studies were performed with fibroblasts from patients with isolated deficiencies of the respective enzymes. The results are shown in table V. Fusion of fibroblasts of the propositus with Morquio A fibroblasts did not produce any increase ln GalNAc-6-S sulfatase activity. Fusion of the patients fibroblasts with sialidosis fibroblasts, however, resulted in a significant elevation of neuraminidase activity.
In fibroblasts of the patient, the content of bound, water extractable sialic acid (2.86 nmol/mg protein) was not increased (normal controls 6.04 and 6.12 nmol/mg protein, respectively). In the urine of the patient, the content of bound sialic acid, 0.357 bmol/mg creatinine, was somewhat increased (normal controls: 0.074 and 0.084 &mol/mg, respectively), but amounted for only about 10 8 of the sialic acid content in the urine of a sialidosis patient (3.51 bmol/mg creatinine) .
The results on patient M.Q. prompted us to reinvestigate other Morquio A cell lines. Neuraminidase activitv was measured in 10 different Morquio A cell strains. As shown in table I, two cell lines were within the Is-, six cell lines within the 2s-, and two cell lines below the 2s-ranges of mean normal neuraminidase activity.
DISCUSSION
This report describes a patient with coexistent deficiencies of GalNAc-6-S sulfatase and of slvco~rotein neuraminidase in fibroblast homogenates. The ~a l N~c -6 k sulfatase deflclency appears to have caused the development of the cllnlcal svmptoms typical of Morquio disease. The neuraminidase deficiency; bn the other hand, has been without apparent clinical consequences up to now, perhaps because of the relatively high residual activity as compared to that found in sialidosis patients. Neuraminidase deficiency, however, could not be observed in peripheral leucocytes (26) . It seems therefore possible that the primary metabolic lesion is a genetic defect of GalMAc-6-S sulfatase, and that the neuraminidase deficiency is a secondary event. Support for this assumption comes from the finding of a gene dosage effect for the sulfatase, but not the sialidase, as only the former activity was reduced in obligate heterozygotes.
Investigation of further Morquio A cell lines revealed the reduced neuraminidase activity not being unique for this Morquio patient. In two Morquio A patients, both with the severe form of the disease, neuraminidase activity was almost as low as in patient M.Q., whereas the neuraminidase activity of six patients was in the low normal range. Interestingly, both patients with the highest neuraminidase activity exhibit the mild form of Morquio disease type A.
What is the cause of the reduced sialidase activity? The fusion experiments suggest that two different gene mutations are involved in the neuraminidase deficiencies of our patient and a patient with sialidosis (mucolipidosis I). In contrast,GalNAc-6-S sulfatase deficiency was not corrected after hybridization with Morquio A fibroblasts. indlcatins that the mutation should be within this particular gene. ~ho;gh the localization of the genes coding for neuraminidase and GalNAc-6-S sulfatase is as yet unknown, a linkaqe either between the structural aenes o; between the structural gene for the sulfatase and another-gene involved in the expression of the neuraminidase seems possible.
Another likely explanation for the neuraminidase deficiency could be inhibition by storage material. It had been shown by Mian et al. (15) that C. perfringens neuraminidase can be inhibited by sulfated glycopeptides. However, Morquio fibroblasts store only minute amounts of chondroitin sulfate and do not produce keratan sulfate (14) . Mixing experiments gave no indication of the presence of a reversibly acting inhibitor in the patient's fibroblasts (table 111) . On the other hand, fibroblasts from other mucopolysaccharidosis patients with excessive storage of sulfated qlycosaminoglycans exhibited normal or only marginally reduced neuraminidase activity (table I) . Thus, the reason for the neuraminidase deficiency in fibroblasts of some patients with Morquio A disease remains speculative at present.
Our observations are of obvious relevance for the biochemical diagnosis of the neuraminidase deficiency diseases, particularly, as cultured fibroblasts are the preferred material for testina. Thus, if neuraminidase deficiency should be detected, it would be necessary to determine additional enzyme activities in order to decide if one is dealing with a sialidosis with an "isolated" neuraminidase deficiency, a combined 5-galactosidase/neuraminidase defect, a mucolipidosis I1 or 111, or, as in the present case, a rnucopolysaccharidosis, type Morquio A. This is of particular importance with respect to the prognosis affixed to a certain diagnosis, as the clinical courses of the different diseases vary greatly.
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